Evidence map›Paper›PMID 24789179›Full record

ArticleJournal of clinical microbiology2014

Emergence of new CMRSA7/USA400 methicillin-resistant Staphylococcus aureus spa types in Alberta, Canada, from 2005 to 2012.

Vincent Li, Linda Chui, Kimberley Simmonds, Thuha Nguyen, George R Golding, Wadieh Yacoub, Christina Ferrato, Marie Louie

Open access · bronzeAbstract read
In one paragraph

Article in Journal of clinical microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Vincent LiProvincial Laboratory for Public Health, Edmonton, Alberta, Canada.
Linda ChuiProvincial Laboratory for Public Health, Edmonton, Alberta, Canada Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada Linda.Chui@albertahealthservices.ca.
Kimberley SimmondsEpidemiology and Surveillance Team, Alberta Ministry of Health, Edmonton, Alberta, Canada.
Thuha NguyenEpidemiology and Surveillance Team, Alberta Ministry of Health, Edmonton, Alberta, Canada.
George R GoldingNational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
Wadieh YacoubFirst Nations and Inuit Health Branch, Health Canada, Alberta Region, Edmonton, Alberta, Canada.
Christina FerratoProvincial Laboratory for Public Health, Calgary, Alberta, Canada.
Marie LouieProvincial Laboratory for Public Health, Calgary, Alberta, Canada Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada.
Provincial Laboratory of Public Health · CAMinistry of Health · CAHealth Canada · CAPublic Health Agency of Canada · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) has become one of the most significant pathogens affecting global public health and health care systems. In Canada and the United States, the spread of MRSA is primarily attributed to a single dominant epidemic clone: CMRSA10/USA300. Despite this, the CMRSA7/USA400 epidemic clone has been reported to be the predominate epidemic clone in several Canadian provinces and some parts of the United States. This study examined the epidemiology of CMRSA7/USA400 MRSA in Alberta, Canada, from June 2005 to December 2012. Molecular characterization of CMRSA7/USA400 isolates was done using spa, SCCmec, PVL, and PFGE typing and identified two predominant spa types in Alberta: t128 and t1787. Although closely related, these spa types have distinct geographic distributions. From 2010 to 2012, the number of t128 infections has remained stable while there has been a nearly 3-fold increase in the number of provincial t1787 infections, accompanied by 10-fold increases in t1787 infection rates in some communities. Most t128 and t1787 patients were First Nations or Inuit people, and isolates were usually from skin and soft tissue infections in outpatients. t128 patients were significantly older than t1787 patients. Antimicrobial susceptibility testing showed higher mupirocin resistance in t1787 than in t128 MRSA. Improved strategies to reduce or stabilize t1787 infections in Alberta are needed.

Indexed as

Molecular TypingAdolescentAdultAgedAged, 80 and overAlbertaAnti-Bacterial AgentsChildChild, PreschoolDrug Resistance, BacterialFemaleGenotypeHumansInfantInfant, NewbornMaleAnti-Bacterial AgentsMupirocin

Identifiers

PMID24789179
PMCPMC4097756
OpenAlexW2011810928

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.